EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc.

EYPT

Rank in Stocks #24959
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the... EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Share Price
$0.3195
Last synced: 2026-11-12
Market Cap
$28.51M
Change (1 day)
-10.40%
Change (1 year)
-97.57%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade EyePoint Pharmaceuticals, Inc. (EYPT)

Category

Healthcare
Operating Margin for EyePoint Pharmaceuticals, Inc. (EYPT)
Operating Margin as of November 2026 TTM: -13,642.03%
According to EyePoint Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is -13,642.03%. At the end of 2025 the company had an operating margin of -775.98%.
Operating Margin history for EyePoint Pharmaceuticals, Inc. from 2001 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -13,642.03% 1,658.04%
2025 -775.98% 130.22%
2024 -337.06% 106.62%
2023 -163.13% -32.21%
2022 -240.65% 60.82%
2021 -149.64% 38.20%
2020 -108.28% -53.93%
2019 -235.02% -73.51%
2018 -887.34% 260.12%
2017 -246.40% -81.67%
2016 -1,344.07% -5,660.90%
2015 24.17% -106.22%
2014 -388.42% -30.81%
2013 -561.41% -21.48%
2012 -715.00% 254.89%
2011 -201.47% -610.83%
2010 39.44% -203.46%
2009 -38.12% -94.68%
2008 -716.37% -54.95%
2007 -1,590.25% -15.80%
2006 -1,888.63% 15.95%
2005 -1,628.79% -30.73%
2004 -2,351.37% -51.40%
2003 -4,838.64% 1,291.69%
2002 -347.68% 0.00%
2001 0.00% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -99.99%
US
33.87% -100.00%
US
-116.04% -99.99%
US
25.57% -100.00%
AU
31.23% -100.00%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about EyePoint Pharmaceuticals, Inc.'s operating margin

What is EyePoint Pharmaceuticals, Inc.'s operating margin?

EyePoint Pharmaceuticals, Inc.'s operating margin is -13,642.03%, as of Nov 2026.

What was EyePoint Pharmaceuticals, Inc.'s operating margin in 2025?

In 2025, EyePoint Pharmaceuticals, Inc.'s operating margin was -775.98%, compared with -337.06% in 2024.

How has EyePoint Pharmaceuticals, Inc.'s operating margin changed since 2020?

From 2020 to 2025, EyePoint Pharmaceuticals, Inc.'s operating margin was highest in 2020 (-108.28%) and lowest in 2025 (-775.98%).

How does EyePoint Pharmaceuticals, Inc.'s operating margin compare with similar companies?

EyePoint Pharmaceuticals, Inc.'s operating margin (-13,642.03%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.